Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR39 | O43194 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309688 | 0.85 | MAPK1 (0.46) | GPR39FYNCYP1A2MAPTCYP2C9 | |
| SCHEMBL24309850 | 0.83 | AXL (0.35) | AXLJAK1JAK3 | |
| SCHEMBL24309763 | 0.82 | USP1 (0.33) | AXLJAK1JAK3 | |
| SCHEMBL24310671 | 0.82 | JAK2 (0.36) | AXLJAK1JAK3 | |
| SCHEMBL24310347 | 0.82 | GPR39 (0.39) | GPR39FYNCYP1A2MAPTCYP2C9 | |
| SCHEMBL24309764 | 0.82 | USP1 (0.32) | JAK1JAK3 | |
| SCHEMBL29567073 | 0.80 | HTR1A (0.43) | GPR39CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL24309659 | 0.80 | HTR1A (0.43) | GPR39CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL24309345 | 0.80 | JAK1 (0.32) | AXLJAK1JAK3 | |
| SCHEMBL24310657 | 0.80 | AXL (0.31) | AXLJAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |